Mr. Luc Mongeau reports

CANOPY GROWTH RELAUNCHES TWEED BRAND IN GERMANY WITH NEW MTL CANNABIS STRAIN LINEUP, MARKING FIRST INTERNATIONAL RELEASE FOLLOWING ACQUISITION

Canopy Growth Corp. has relaunched the Tweed brand in the German medical market, alongside the introduction of three cannabis strains developed by MTL Cannabis Corp., a wholly owned subsidiary of the company. The dual milestone represents the company's first international product release following its recent acquisition of MTL.

Pablo's Revenge

The Tweed brand relaunch -- now powered by MTL's premium genetics -- signals the company's commitment to leveraging the full equity of its legacy brand in key international markets and comes as Germany's medical cannabis market continues to expand rapidly, approaching $1-billion in annual value in 2025. The MTL acquisition has enhanced Canopy Growth's capacity to meet rising demand in key international markets, including Germany, while reintroducing a brand that physicians and patients have come to trust.

"Germany is one of the fastest-growing medical cannabis markets globally and demand continues to scale rapidly. The relaunch of our Tweed brand is a meaningful moment for us, reflecting both the strength of what we have built, and our commitment to delivering consistent, high-quality cannabis that physicians can prescribe with confidence and patients can rely on as part of their care. We believe the European Union represents a tremendous opportunity for Canopy and Germany is just the beginning," said Luc Mongeau, chief executive officer, Canopy Growth.

The initial launch includes three cultivars -- Pablo's Revenge, Dante'z Inferno and Frost'd Flakes -- selected for their quality and consistency. Up to five MTL-derived strains are expected to be introduced in June, 2026, with further portfolio expansion planned throughout the year.

The company also announced today that it has been granted a management cease trade order effective as of May 28, 2026, by its principal regulator, the Ontario Securities Commission under National Policy 12-203 -- Management Cease Trade Orders. This follows the company's announcement on May 15, 2026, regarding certain non-cash technical errors in the company's accounting relating to certain share-settled warrants of the company with exercise prices denominated in United States dollars, first issued during the fiscal year ended March 31, 2024. The company intends to refile the relevant financial statements in its annual report on Form 10-K for the fiscal year ended March 31, 2026, which is expected to be filed with Canadian securities regulators and with the United States Securities and Exchange Commission (the SEC) on June 15, 2026.

About Canopy Growth Corp.

Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. Its portfolio of owned and licensed brands including Tweed, 7Acres, Doja, Deep Space, Deelish, Claybourne, MTL Cannabis, Low Key by MTL and R'belle, as well as category defining Storz & Bickel, delivers innovative products to consumers across Canada and beyond.

Canopy Growth is Canada's leading provider of medical cannabis services through Canada House Clinics and serves patients on-line via Abba Medix. The company also holds unconsolidated, non-controlling interest in Canopy USA LLC, which provides exposure to the United States THC market.

Committed to quality, responsible use and community, Canopy Growth is shaping a future where cannabis is embraced for its potential to enhance well-being.

We seek Safe Harbor.